Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that the EXPAND clinical trial has enrolled over 2,000 patients, more than ...
The test will enable physicians to assess if post-surgery cancer patients need to receive treatment to minimize the risk of ...
Newser on MSN
For cancer survivors, this type of test may be key
Wall Street's newest cancer bet isn't about finding tumors early, but about making sure they're really gone. The Wall Street ...
SAN CARLOS, Calif., Dec. 19, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Medicare has finalized its local coverage determination ...
SAN CARLOS, Calif., Sept. 11, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal ...
Natera says it has begun making good on its priorities for 2021, which include expansions in noninvasive prenatal testing (NIPT), transplant rejection testing, minimal residual disease (MRD) cancer ...
SAN CARLOS, Calif., Oct. 2, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that the company's ...
One company has a big early lead in blood tests that detect cancer returning in survivors.
More than three years into a lawsuit accusing competitor Natera of disparaging its cancer blood test, Guardant Health has emerged victorious. As both companies reported Monday, a federal jury in the U ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results